The purpose of the study is to examine the safety and effectiveness of the drug combination of Myocet, paclitaxel and trastuzumab compared to paclitaxel and trastuzumab without Myocet, as first line treatment for patients with metastatic HER2+ breast cancer.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
363
Progression-Free Survival
Overall Survival
Safety
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Scripps Cancer Center Clinical Research
San Diego, California, United States
University of Colorado
Aurora, Colorado, United States
Northwest Hematology/Oncology Associates
Coral Springs, Florida, United States
Osceola Cancer Center
Kissimmee, Florida, United States
UM/Sylvester Cancer Center
Plantation, Florida, United States
John B. Amos Cancer Center
Columbus, Georgia, United States
Clintell, Inc
Skokie, Illinois, United States
Hutchinson Clinic P.A.
Hutchinson, Kansas, United States
Western Maryland Health System
Cumberland, Maryland, United States
Brody School of Medicine @ ECU
Greenville, North Carolina, United States
...and 95 more locations